Related Experiment Video
Updated: Mar 6, 2026
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
Published on: August 18, 2014
Does Systemic Disease Aggravate the Severity of Dry Mouth by Anticholinergics in Overactive Bladder Patients?
Keon-Cheol Lee1, Bong-Mo Seong2
1Department of Urology, Inje University School of Medicine, Ilsanpaik Hospital, Goyang, Korea.
Purpose:
In overactive bladder (OAB) patients with systemic diseases, dry mouth tends to be more prominent owing to the effects of systemic diseases or related medications. We evaluated how systemic diseases affect dry mouth before and after anticholinergic treatment.
Materials And Methods:
OAB patients were enrolled in this study. The patients were divided according to the presence or absence of systemic diseases. Patients with systemic diseases were sub-grouped by the number of systemic diseases (only one or more than one disease). OAB symptoms score (OABSS), visual analogue scale (VAS) score for dry mouth, and body mass index (BMI) were measured. The statistical assessments were donewith independent T-tests and ANCOVAs.
Results:
One hundred and four OAB patients were enrolled in this study. Seventy (67.3%) patients had systemic diseases and thirty-four (32.7%) patients did not. Age and BMI were higher in the systemic diseases group. The baseline VAS score of OAB in the systemic diseases group (15.9 ± 19.5) was higher than that in the OAB without systemic diseases group (4.1 ± 6.4) (P = .002). Even after age and BMI adjustment, the difference was significant. The follow-up VAS score was also different (P = .028), but the change in VAS score was not different (P = .280). In a sub-analysis, the change in VAS score in the group with two or more systemic diseases (23.6 ± 18.1) was higher than that in the group with only one systemic disease (12.5 ± 13.2) (P = .012).
Conclusion:
The severity of xerostomia after treatment with anticholinergics in OAB increases in patients with one systemic disease parallel to its severity before starting treatment. However, in patients with two or more systemic disease the magnitude of change in xedrostomia score is higher that we would expect in patients with no or one systemic diasese.
Insights
Systemic diseases worsen dry mouth in overactive bladder (OAB) patients. Those with multiple conditions experience a greater increase in xerostomia (dry mouth) after anticholinergic treatment compared to those with none or one condition.
Area of Science:
- Urology
- Pharmacology
Background:
- Overactive bladder (OAB) patients with systemic diseases often experience more severe dry mouth.
- Systemic diseases or their medications can exacerbate xerostomia in OAB patients.
Purpose of the Study:
- To evaluate the impact of systemic diseases on dry mouth severity in OAB patients.
- To assess changes in dry mouth before and after anticholinergic treatment in relation to systemic disease burden.
Main Methods:
- 104 OAB patients were categorized based on the presence and number of systemic diseases.
- Dry mouth severity (Visual Analogue Scale - VAS), OAB Symptom Score (OABSS), and Body Mass Index (BMI) were measured.
- Statistical analyses included independent t-tests and ANCOVAs.
Main Results:
- Patients with systemic diseases had significantly higher baseline dry mouth VAS scores (15.9 vs. 4.1, P=.002) compared to those without.
- While follow-up VAS scores differed (P=.028), the change in VAS score was not significantly different between groups overall (P=.280).
- Patients with two or more systemic diseases showed a significantly greater increase in dry mouth VAS score (23.6) compared to those with only one systemic disease (12.5, P=.012).
Conclusions:
- Anticholinergic treatment for OAB can increase xerostomia, with severity correlating to pre-treatment levels in patients with one systemic disease.
- Patients with multiple (two or more) systemic diseases exhibit a more pronounced increase in dry mouth severity post-treatment than expected.
- The burden of systemic disease significantly influences the experience of dry mouth in OAB patients undergoing anticholinergic therapy.
More Related Videos
03:50Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
Published on: August 18, 2023
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
Related Concept Videos
01:28Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:26Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
01:24Cholinergic Antagonists: Pharmacokinetics
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions